Related Experiment Video

Updated: Jun 10, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy

Claudio A Muratore1, Adrian Baranchuk

  • 1Department of Cardiology, Arrhythmia Service, Hospital Fernandez, Buenos Aires, Argentina. cmuratore@intramed.net

Vascular Health and Risk Management
|August 24, 2010
PubMed

Insights

Chagas

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Parasitology

Background:

  • Chagas' disease, caused by Trypanosoma cruzi, affects 18 million people in Latin America.
  • The parasitic infection commonly leads to severe cardiac complications, including heart failure and arrhythmias.
  • Chagas' cardiomyopathy significantly increases the risk of stroke, thromboembolism, and sudden cardiac death.

Purpose of the Study:

  • To review current and emerging treatments for Chagas' cardiomyopathy.
  • To focus on the management of heart failure and arrhythmias in affected patients.
  • To evaluate the potential of antiparasitic therapy in preventing cardiovascular disease progression.

Main Methods:

  • Literature review of therapeutic options for Chagas' cardiomyopathy.
  • Analysis of pharmacological, cellular, and surgical interventions for heart failure.
  • Review of antiarrhythmic strategies, including drugs, ablation, and devices.
  • Examination of evidence for antiparasitic treatment in cardiovascular prevention.

Main Results:

  • Current heart failure management includes drugs, stem cells, and transplantation.
  • Arrhythmia control involves antiarrhythmic drugs, catheter ablation, and intracardiac devices.
  • Evidence is reviewed for antiparasitic treatment's role in preventing cardiac complications.

Conclusions:

  • Effective management of Chagas' cardiomyopathy requires addressing both heart failure and arrhythmias.
  • Emerging therapies offer new hope for patients with advanced cardiac involvement.
  • Further research is needed to confirm the role of antiparasitic treatment in cardiovascular prevention.

Keywords:
chronic chagasic cardiomyopathyemerging therapeutic options

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...